true FY 0001362703

 0001362703

 2022-10-01
 2023-09-30

 0001362703

 2023-03-31

 0001362703

 2024-01-28

 utr:sqft

 UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 Washington,
D.C. 20549

 FORM
 10-K/A

 (Amendment
No. 1)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the fiscal year ended: September 30, 2023

 or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For
the transition period from _________ to ________

 Commission
File Number: 000-52218

 Theralink
Technologies, Inc.

 (Exact
name of registrant as specified in its charter)

 Nevada

 20-2590810

 (State
 or other jurisdiction

 of
 incorporation)

 (I.R.S.
 Employer

 Identification
 Number)

 15000
 W. 6 th Avenue,
 Suite

 Golden,
 CO 80401

 (888) 585-4923

 (Address
 of principal executive offices and zip code)

 (Registrant's
 telephone number, including area code)

registered pursuant to Section 12(b) of the Act: None

registered pursuant to Section 12(g) of the Act:

 Common Stock, Par Value $0.0001

 (Title
of Class)

by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes No

by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes No

by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller
reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large
 accelerated filer

 Accelerated
 filer

 Non-accelerated
 filer

 Smaller
 reporting company

 Emerging
 growth company

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.

 If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements.

by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No

 The
aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $ 2.5 million
as of March 31, 2023.

 The
registrant had 6,151,499,919 shares of its common stock, par value $0.0001, issued and outstanding as of January 28, 2024.

 Audit
 Firm Id

 Auditor
 Name:

 Auditor
 Location

 Salberg & Company, P.A

 Boca
 Raton, Florida

 EXPLANATORY NOTE

 This Amendment No. 1 on Form
10-K/A (the "Amendment") amends the Annual Report on Form 10-K (the "2023 Form 10-K") of Theralink Technologies,
Inc. (the "Company") for the year ended September 30, 2023 ("Fiscal 2023"), as filed with the Securities and Exchange
Commission (the "SEC") on January 5, 2024. We are filing this Amendment to amend Part III of the 2023 Form 10-K to include
the information required by and not included in Part III of the 2023 Form 10-K because we do not intend to file our definitive proxy statement
within 120 days of the end of Fiscal 2023.

 In addition, the Exhibit
Index in Item 15 of Part IV of the 2023 Form 10-K is hereby amended and restated in its entirety and currently dated certifications required
under Section 302 of the Sarbanes-Oxley Act of 2002 are filed as exhibits to this Amendment. Because no financial statements are contained
within this Amendment, we are not filing currently dated certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 Except as described above,
no other changes have been made to the 2023 Form 10-K. The 2023 Form 10-K continues to speak as of the date of the 2023 Form 10-K, and
we have not updated the disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the 2023
Form 10-K other than as expressly indicated in this Amendment.

 PART
III

 ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 Board
of Directors and Executive Officers

 The
following table sets forth the names, positions and ages of our directors and executive officers as of the date of this report.

 Name

 Age

 Position

 Faith

 Chief
 Executive Officer, Chief Operating Officer, and President

 Chief
 Financial Officer and Director

 Jeffrey
 Busch

 Chairman
 of the Board

 Yvonne
 C. Fors

 Danica
 Holley

 Mick
 Ruxin, M.D.

 Matthew
 Schwartz

 Biographical
information concerning the directors and executive officers listed above is set forth below. The information has been provided to us
about all the positions they hold, their principal occupation and their business experience for the past five years. In addition to the
information presented below regarding each director's specific experience, qualifications, attributes and skills that led our Board
to conclude that they should serve as a director, we also believe that all of our directors have a reputation for integrity, honesty
and adherence to high ethical standards. Each has demonstrated business acumen and an ability to exercise sound judgment, as well as
a commitment of service to our Company and our Board. Each director is to be elected at our annual meeting of shareholders and holds
office until the next annual meeting of shareholders, or until their qualified successor is elected.

 Faith

 Ms.
Zaslavsky was appointed as the Company's CEO on June 26, 2023. She has also served as President and Chief Operating Officer since
December 5, 2022. Prior to her current position, Ms. Zaslavsky served as President of Oncology for Myriad Genetic Laboratories, (NASDAQ-
MYGN). Her responsibilities included overseeing all commercial functions which include leading Medical Services, Medical Affairs, National
and Enterprise Accounts and Sales and Marketing. She has spent 22 years leading and transforming teams, designing solutions for physicians
to support care and advocating for patients facing a journey with cancer. She received a Business Administration degree from Washington
State University. Ms. Zaslavsky also serves on the board of directors of the American Society of Breast Surgeons Foundation.

 On
May 5, 2023, Mr. Kucharchuk was appointed as the Company's Chief Financial Officer. Mr. Kucharchuk has served as a director of
our Company since June 2020. Mr. Kucharchuk also served as our Chief Financial Officer from August 2020 until September 2020. Mr. Kucharchuk
was previously the Chief Executive Officer and Chief Financial Officer of OncBioMune, Inc. prior to the Asset Sale. Mr. Kucharchuk is
currently the Chief Operating Officer and on the Board of Directors of Adhera Therapeutics, Inc. (OTCQB: ATRX), a late clinical stage
biotechnology company, with an asset in the Parkinson's space. Mr. Kucharchuk is a graduate of Louisiana State University and Tulane
University's Freeman School of Business, where he earned an MBA with a Finance Concentration. Mr. Kucharchuk's role as a
former executive officer of our Company gives him insights into our day-to-day operations and a practical understanding of the issues
and opportunities that face us which uniquely qualify him to serve as a member of our Board.

 Mick
Ruxin, M.D.

 Dr.
Ruxin has served as a director of the Company since June 2020. Previously, he was the Chief Executive Officer of the Company from June
2020 to June 2023 and currently serves as the Company's Chief Medical Officer. Dr. Ruxin was the Chief Executive Officer and President
of Avant prior to the Asset Sale to Theralink. Previously, he was a strategic advisor to Avant and was the Chairman, CEO and Founder of
Global Med Technologies, Inc. (GLOB). He grew GLOB from a foundational concept to an international medical software company, specializing
in FDA approved software, with specific diagnostic capabilities, and serving over 30 countries on 4 continents. Under his leadership,
GLOB had its initial financing, its initial public offering and subsequent follow-on financings. Dr. Ruxin also founded PeopleMed, Inc.,
a validation and chronic disease management software subsidiary of GLOB. In addition, he conceived and executed the acquisition and financing
of Inlog, a French software company serving the EU, becoming the Directeur General responsible for European Operations—and eDonor,
a US based regulated software company serving domestic and international blood donor centers. Prior to Dr. Ruxin engineering the sale
of GLOB to a NYSE company, Haemonetics Corp. (HAE), he led his team to national prominence by being awarded the #1 position in quality
of product and customer service against billion-dollar software companies, rated by an industry-respected, independent software rating
service. After GLOB's acquisition by Haemonetics, Dr. Ruxin was asked to stay with the company through the transition. Dr. Ruxin
was on the Executive Management Team (EMT) at Haemonetics for approximately 6 months after the merger. The EMT was responsible for diagnostic
strategies and identified domestic and international software opportunities for the company. Before founding Global Med Technologies,
Dr. Ruxin founded and was President and CEO of DataMed International, Inc. (DMI), a private, international drugs of abuse management
company (from 1989-1997). DMI's clients included FedEx, International Multi-Foods, Los Alamos National Laboratories, Chevron, ConAgra,
Nestles and AT&T, among over 500 other companies. Dr. Ruxin was one of the first 10 certified Medical Review Officers in the country,
and he participated in writing the Federal legislation for drugs of abuse testing. Dr. Ruxin received his M.D. degree from the University
of Southern California School of Medicine and his B.A degree in Philosophy from the University of Pittsburgh.

 Jeffrey
Busch

 Mr.
Busch has served as the Chairman of our Board since June 2020. Mr. Busch is the current Chairman and CEO of Global Medical REIT, a NYSE
listed (NYSE:GMRE) and publicly traded company which acquires licensed medical facilities. Mr. Busch has been a Presidential Appointee,
entrepreneur and active investor in various asset classes, including medical and pharmaceutical since 1985. Mr. Busch has had a distinguished
career in public service, which included serving as a Chief of Staff to a United States Congressman and serving in senior positions in
two U.S. Presidential Administrations. Mr. Busch oversaw hundreds of millions of dollars in economic development programs. Mr. Busch
represented the United States before the United Nations in Geneva, Switzerland. Mr. Busch has served as a top advisor to several publicly
traded medical companies and has worked in the medical, blood supply and management fields. Mr. Busch also served as President of the
Safe Blood International Foundation, where he oversaw the establishment of medical facilities in 35 developing nations, including China.
These facilities were funded by the U.S. Centers for Disease Control and Prevention, USAID, Chinese government and corporate and private
entities. Mr. Busch is a graduate of the New York University Stern School of Business, holds a Master of Public Administration specializing
in health care from New York University, and a Doctor of Jurisprudence from Emory University.

 Yvonne
C. Fors

 Ms.
Fors has served as a director of our Company since June 2020. Ms. Fors is the current Chief Financial Officer and Vice President of Finance
for Ashton Capital Corporation. Her achievements at Ashton include growing the company through acquisitions, real estate development
and investments. In her role, she establishes relationships and collaborates with banks and other financial institutions to leverage
the assets of the corporation to fund future growth. Ms. Fors currently serves on the Board of Directors of Ashton Capital, SaviBank,
Savi Financial Corporation and GaffTech. She is also actively involved in SWAN Investments, an early-stage investment fund located in
Seattle. Previously, Ms. Fors was the Controller and Manager of four medical clinics in Las Vegas, Nevada. Ms. Fors holds a Bachelor
of Science degree in Accounting from the University of Nevada, Las Vegas.

 Matthew
Schwartz, MD

 Dr.
Schwartz has served as a director of our Company since April 2022. Dr. Schwartz is a practicing Radiation Oncologist with Comprehensive
Cancer Centers of Nevada (CCCN) since 2006. Through his service on the Board of Directors of CCCN as well as the Marketing Chairman,
he helped grow CCCN to the largest Oncology group in Nevada with 64 providers in 12 locations. He is also the Chairman of the Board of
Managers and co-founder of the Las Vegas Cyberknife at Summerlin which offers state of the art Radiosurgical treatments. Dr. Schwartz
was a member of the McKesson Specialty Health Radiation Executive Committee, and he served on the Radiation Oncology Leadership Council
of US Oncology. Dr. Schwartz was awarded Alumni of the Year from the UNLV College of Sciences. He received his MD from the University
of Nevada School of Medicine, and he was a Resident at Yale University Department of Internal Medicine and McGill University School of
Medicine where he was Chief Resident. Dr. Schwartz has been the Principal Investigator on Clinical Research Studies in Oncology and has
multiple peer reviewed publications.

 Danica
Holley

 Ms.
Holley has served as a director of the Company since April 2022. Ms. Holley serves as the Chief Operating Officer of Global Medical REIT
Inc. (NYSE: GMRE) since March 2016. As COO, she has shepherded the organization's growth from infancy, IPO, to now over $1.4 billion
gross real estate assets under management. Ms. Holley leads the operational, risk and ESG initiatives at GMRE. Ms. Holley's management
and business development experience spans more than 18 years with an emphasis on working in an international environment. She has extensive
experience in international program management, government procurement, and global business rollouts and start-ups. As Executive Director
for Safe Blood International Foundation, from April 2008 to July 2016, she oversaw national health initiatives in Africa and Asia, including
an Ebola response project. Ms. Holley has more than two decades of experience managing multinational teams for complex service delivery
across disciplines. Ms. Holley currently serves on the Board of Directors for Mobile Infrastructure Corporation, where she is a member
of the audit, compensation and nominating and governance committees. She received a B.S.F.S from the Edmund Walsh School of Foreign Service
at Georgetown University in International Law, Politics and Organization, an African Studies Certificate and Arabic Proficiency (May
1994). She studied International Organization at the School for International Training, Brattleboro, Vermont and Rabat, Morocco (January
1993 to June 1993). She is an ICF certified executive leadership coach and an alumna of Georgetown University's Graduate Executive
Leadership Coaching Program (September 2010). In 2018, she completed Harvard Business School's Finance for Senior Executives program.

 Family
Relationships

 There
are no family relationships between any of the executive officers and directors.

 Delinquent
Section 16(a) Reports

 Section
16(a) of the Exchange Act requires our officers, directors, and persons who beneficially own more than ten percent (10%) of our outstanding
common stock, to file initial reports of ownership and reports of changes in ownership with the SEC. Such persons are required by SEC
regulations to furnish us with all copies of Section 16(a) forms they file.

 Based
solely on our review of the forms furnished to us and written representations from certain reporting persons, we believe that all filing
requirements applicable to our directors, executive officers, and persons who own more than 10% of our common stock were timely filed
during fiscal 2023, except:

 Faith Zaslavsky filed a late Form 3 on December 19, 2023 for a transaction dated December 5, 2022;

 Matthew Schwartz filed a late Form 4 on January 26, 2024for
a transaction dated November 29, 2022;

 Danica Holley filed a late Form 4 on January 26, 2024for a
transaction dated November 29, 2022; and

 Jeffrey Busch filed a late Form 4 on February 2, 2024 for transactions
dated November 29, 2022 and April 22, 2023.

 Code
of Ethics

 We
have not adopted a code of ethics because our Board believes that our small size does not merit the expense of preparing, adopting and
administering a code of ethics. Our Board intends to adopt a code of ethics when circumstances warrant.

 Involvement
in Certain Legal Proceedings

 No
director, executive officer, promoter or person of control of our Company has, during the last ten years: (i) been convicted in or is
currently subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); (ii) been a party to a civil
proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or mandating activities subject to any Federal or state securities
or banking or commodities laws including, without limitation, in any way limiting involvement in any business activity, or finding of
any violation with respect to such law, nor (iii) been a party to any bankruptcy petition filed by or against the business of which such
person was an executive officer or a general partner, whether at the time of the bankruptcy or for the two years prior thereto.

 We
are not engaged in, nor are we aware of any pending or threatened litigation in which any of our directors, executive officers, affiliates
or owner of more than 5% of our common stock is a party adverse to us or has a material interest adverse to us.

 Corporate
Governance

 Term
of Office

 Each
director of our Company is to serve for a term of one year ending on the date of the subsequent annual meeting of stockholders following
the annual meeting at which such director was elected. Notwithstanding the foregoing, each director is to serve until their successor
is elected and qualified or until his or her death, resignation or removal.

 Committees
of the Board

 Our
Board held six formal meetings during the year ended September 30, 2023. All other proceedings of our Board were conducted by resolutions
consented to in writing by all the directors and filed with the minutes of the proceedings of the directors. Such resolutions consented
to in writing by the directors entitled to vote on that resolution at a meeting of the directors are, according to the corporate laws
of the State of Nevada and our By-laws, as valid and effective as if they had been passed at a meeting of our directors duly called and
held. During 2023, each incumbent director attended 75% or more of the meetings of our Board.

 We
currently do not have nominating or compensation committees or committees performing similar functions, nor do we have a written nominating
or compensation committee charter. Our Board does not believe that it is necessary to have such committees because the functions of such
committees can be adequately performed by our Board.

 We
do not have any defined policy or procedure requirements for shareholders to submit recommendations or nominations for directors. We
do not currently have any specific or minimum criteria for the election of nominees to our Board and we do not have any specific process
or procedure for evaluating such nominees. Our Board assesses all candidates, whether submitted by management or shareholders, and makes
recommendations for election or appointment.

 A
shareholder who wishes to communicate with our Board may do so by directing a written request to the address appearing on the first page
of this annual report.

 Audit
Committee and Audit Committee Financial Expert

 We
do not have a standing audit committee at the present time. Our Board has determined that we do not have a board member that qualifies
as an "audit committee financial expert" as defined in Item 407(d)(5)(ii) of Regulation S-K.

 Our
Board fulfills the functions of an audit committee. We believe that our Board is capable of analyzing and evaluating our financial statements
and understanding internal controls and procedures for financial reporting. The Board does not believe that it is necessary to have an
audit committee because we believe that the functions of an audit committee can be adequately performed by the Board. In addition, we
believe that retaining an independent director who would qualify as an "audit committee financial expert" would be overly
costly and burdensome and is not warranted in our circumstance given the early stages of our development.

 ITEM
11. EXECUTIVE COMPENSATION

 Summary
Compensation

 For
our fiscal year ended September 30, 2023, our Named Executive Officers were:

 (i)

 Faith Zaslavsky, our Chief Executive Officer, who has served
as our Chief Executive Officer since June 26, 2023, and served as the Company's President and Chief Operating from December 5,
2022, until her appointment as CEO on June 26, 2023;

 (ii)

 Andrew Kucharchuk, our Chief Financial Officer, has served
as our Chief Financial Officer since May 2023;

 (iii)

 Mick Ruxin, M.D., our former Chief Executive Officer, who served
as our Chief Executive Officer from June 2020 to June 26, 2023; and

 (iv)

 Thomas E. Chilcott, our former Chief Financial Officer,who
served as our Chief Financial Officer, Secretary and Treasurer from September 2020 to May 5, 2023.

 The
following table shows compensation awarded to, paid to, or earned by our Named Executive Officers for the fiscal years ended September
30, 2023 and 2022:

 SUMMARY
COMPENSATION TABLE

 FOR
OUR NAMED EXECUTIVE OFFICERS

 Stock

 Option

 All

 Name and Principal

 Salary

 Bonus

 Award

 Awards

 Other

 Position

 Year

 ($)

 ($)

 ($)

 ($)(1)

 Compensation

 Total ($)

 (a)

 (b)

 (c)

 (d)

 (e)

 (f)

 (g)

 (h)

 Named Executive Officers

 Faith Zaslavsky

 Chief Executive Officer

 2023

 $
 330,512

 $
 -

 $
 -

 $
 -

 $

 $
 330,512

 2022

 -

 -

 -

 -

 -

 Andrew Kucharchuk

 Chief Financial Officer

 2023

 $
 71,613

 $
 30,000

 $
 -

 $
 -

 $
 21,000
 (2)

 $
 122,613

 2022

 Mick Ruxin

 Chief Executive Officer

 2023

 $
 224,395
 (3)

 $
 -

 $
 -

 $
 936,783
 (4)

 1,161,178

 (prior)

 2022

 $
 300,000
 (3)

 $
 -

 $
 -

 $
 1,972,903

 $
 10,142
 (4)

 2,283,045

 Thomas E. Chilcott

 Chief Financial Officer

 2023

 $
 192,269
 (5)

 $
 150,000

 (5
)

 $
 31,604
 (6)

 373,873

 (prior)

 2022

 $
 259,375
 (5)

 $
 75,000

 (5
)

 $
 397,089

 $

 (6)

 740,918

 (1)

 The
amounts reported under "Option Awards" in the above table reflect the grant date fair value of these awards as determined
in accordance with the Financial Accounting Standards Board's Accounting Standards Codification Topic 718, Compensation –
Stock Compensation, rather than amounts paid to or realized by the named individual. The value of the option awards was estimated using
the Black-Scholes option pricing model. The valuation assumptions used in the valuation of options granted may be found in Note 10 to
our financial statements included in this annual report on Form 10-K for the year ended September 30, 2023.

 (2)

 Consulting
 fees paid to Mr. Kucharchuk for the period October 1, 2023 thru termination of his consulting agreement on April 30, 2024.

 (3)

 On
 June 5, 2020, Dr. Ruxin was appointed to serve as our Chief Executive Officer with an annual salary of $300,000 pursuant to his employment
 agreement dated June 5, 2020. On July 14, 2023, Dr. Ruxin's employment agreement was terminated. As of September 30, 2023,
 the Company had accrued compensation payable to Dr. Ruxin under the agreement totaling $171,128.

 (4)

 Represents
 Dr. Ruxin's severance of $900,000, health insurance allowance totaling $7,937 and accrued paid-time off totaling $28,846 as
 of the date of his employment contract termination.

 (5)

 Mr.
 Chilcott served as the Company's Chief Financial Officer, Secretary and Treasurer until May 5, 2023. On December 6, 2022, the
 Board approved a $150,000 bonus for Mr. Chilcott for the successful filing of the Company's report on Form 10-K for the annual
 period ended September 30, 2022.

 (6)

 Represents
 Mr. Chilcott's health insurance allowance of $7,354 and $24,250 paid for accrued vacation as of the date of his termination
 on May 5, 2023.

 Our
executive officers are reimbursed by us for any out-of-pocket expenses incurred in connection with activities conducted on our behalf.

 Employment
Agreements

 Faith

 On
December 5, 2022, the Company appointed Faith Zaslavsky, as President and Chief Operating Officer of the Company, effective December
5, 2022. In connection with her appointment, on December 5, 2022, the Company and Ms. Zaslavsky entered into an offer letter which provides
that Ms. Zaslavsky's base salary will be $400,000 per year, and that beginning in calendar year 2023 she will be eligible to receive
an annual incentive cash bonus of up to 35% of base salary at the discretion of the Board for the achievement of certain milestones to
be agreed upon by Ms. Zaslavsky and the Company within 90 days of the Effective Date. Upon the Company's creation of a new equity
incentive plan or an increase in the number of shares available under the Company's existing equity incentive plan, Ms. Zaslavsky
will be granted 150,000,000 employee stock options vesting at 20% annually, beginning on the Effective Date. The employee stock options
will have a strike price equal to the closing price of the Company's common stock on the day that the Board approves Ms. Zaslavsky's
stock option package. Ms. Zaslavsky is eligible to participate in the benefit plans and programs generally available to the Company's
employees. Ms. Zaslavsky will also be entitled to reimbursement of reasonable business expenses incurred or paid by her in the performance
of her duties and responsibilities for the Company, subject to any restrictions set by the Company from time to time and to such reasonable
substantiation and documentation as may be specified by the Company from time to time. Ms. Zaslavsky's employment with the Company
is "at-will", and either party can terminate the employment relationship at any time, for or without cause, with or without
notice. The Offer Letter also contains standard restrictive covenants prohibiting Ms. Zaslavsky from engaging in competition with the
Company within the United States during her employment and for a period of 24 months following the termination of her employment with
the Company.

 On
June 28, 2023, the Company appointed Ms. Zaslavsky as the Company's Chief Executive Officer. There was no change to Ms. Zaslavsky's
offer letter as a result.

 On
May 5, 2023, the Company appointed Andrew Kucharchuk, a member of the Board of Directors of the Company, as Chief Financial Officer,
effective May 8, 2023. The agreement proved for a base salary of $180,000 per year. Mr. Kucharchuk is eligible to participate in the
benefit plans and programs generally available to the Company's employees. Mr. Kucharchuk will also be entitled to reimbursement
of all reasonable business expenses incurred or paid by him in the performance of his duties and responsibilities for the Company, subject
to receipt of evidence of such expenses reasonably satisfactory to the Company. Mr. Kucharchuk's employment with the Company is
"at-will", and either party can terminate the employment relationship at any time, for or without cause, with or without
notice.

 On
September 15, 2023, Mr. Kucharchuk's salary was increased to $199,999 per year. In addition, on September 30, 2023, the Company
approved a $30,000 bonus payable to Mr. Kucharchuk for his successful efforts with respect to the Company's Registration Statement
on Form S-4 filed with the United States Securities and Exchange Commission on September 29, 2023.

 Mick
Ruxin, M.D.

 On
June 5, 2020, the Company and Dr. Michael Ruxin entered into an employment agreement (the "Ruxin Employment Agreement") for
Dr. Ruxin to serve as the Company's Chief Executive Officer, President and a director.

 Dr.
Ruxin's Employment Agreement was for a five-year term commencing on June 5, 2020. The agreement could be automatically extended
for one additional year upon the fifth anniversary of the effective date without any affirmative action, unless either party to the agreement
provides at least sixty (60) days' advance written notice to the other party that the employment period will not be extended. Dr.
Ruxin will be entitled to receive an annual base salary of $300,000 and will be eligible for an annual discretionary bonus of 150% of
such base salary. Dr. Ruxin was entitled to participate in any and all benefit plans, from time to time, in effect for senior management,
along with vacation, sick and holiday pay in accordance with the Company's policies established and in effect from time to time.
Per the agreement, on August 16, 2022, the Board granted Dr. Ruxin 469,738,712 options under the 2022 Equity Incentive Plan.

 Dr.
Ruxin was an "at-will" employee subject to termination by the Company at any time, with or without cause. On July 14, 2023,
the Company terminated the employment agreement. In the event Dr. Ruxin's employment is terminated by the Company without Cause
(as defined in the Ruxin Agreement), with Good Reason (as defined in the Ruxin Agreement) or as a result of a non-renewal of the term
of employment under the Ruxin Agreement, Dr. Ruxin shall be entitled to receive the sum of (I) the Severance Multiple (as defined below),
 multiplied by his base salary immediately prior to such termination and (II) a pro-rata portion of his bonus for the year in which
such termination occurs equal to (a) his bonus for the most recently completed calendar year (if any), multiplied by (b) a fraction,
the numerator of which is the number of days that have elapsed from the beginning of such calendar year through the date of termination
and the denominator of which is the total number of days in such calendar year. "Severance Multiple" shall mean 3.0; provided,
however, that if the date of termination occurs on or at any time during the twelve (12)-month period following a Change in Control,
the Severance Multiple shall mean 4.0. In addition, the Company shall accelerate the vesting of any outstanding, unvested equity awards
granted to Dr. Ruxin prior to the date of termination and he shall be entitled to reimbursement of any COBRA payments made during the
18-month period following the date of termination. As a result of Dr. Ruxin's termination, the Company accrued $900,000 of severance
for Dr. Ruxin per the terms of his employment agreement.

 On
July 14, 2023, the Company terminated the employment agreement and entered into a Chief Medical Officer Consulting Agreement with Dr.
Ruxin to serve as the Company's Chief Medical Officer. For compensation for services provided by Dr, Ruxin as a Chief Medical Officer
Consultant (a) the Company shall pay Dr, Ruxin compensation equal to $10,000 per month, (b) the Company shall amend the Dr. Ruxin's
existing option award agreement so that upon a "Separation from Service" instead of having 3 months to exercise the options,
Dr. Ruxin's options shall be exercisable until their expiration date and (c) the Company shall issue Dr. Ruxin options to purchase
shares of the Company's common stock in accordance with the Company's newly planned Equity Incentive Plan, according to the
standard amounts awarded to Chief Medical Officers, as well as taking into consideration the past 5 years of service to the company as
is planned for current employees, subject to Board approval. This Agreement commenced on July 14, 2023 and will continue for one year
and will be brought to the Board of Directors annually for renewal approval based on prior year performance metrics and then for subsequent
one-year periods if not terminated 60 days prior to renewal.

 In
connection with the termination of the Ruxin Employment Agreement, the Company accrued a severance payment due of $900,000. As of September
30, 2023, the Company had aggregate accrued payroll related to Dr. Ruxin's salary deferment and accrued severance payment of $1,099,974
including accrued severance, deferred compensation and paid-time off.

 Outstanding
Equity Awards

 The
following table provides a summary of equity awards outstanding for each of the Named Executive Officers as of September 30, 2023:

 Option Awards

 Stock Awards

 Name

 Underlying
 Unexercised
 Options
 Exercisable (4)

 Underlying
 Unexercised
 Options
 Unexercisable
 (#)

 Equity
 Incentive
 Plan Awards:
 Underlying
 Unexercised
 Unearned
 Options (#)

 Option
 Exercise
 Price ($)

 Option
 Expiration
 Date

 Shares or
 Units of Stock
 That
 Have Not
 Vested (#)

 Market Value
 of Shares or
 Units of Stock
 That
 Have Not
 Vested ($)

 Equity
 Incentive
 Plan
 Awards:
 Unearned
 Shares, Units
 or Other
 Rights That
 Have Not
 Vested (#)

 Equity
 Incentive
 Plan
 Awards:
 Market or
 Payout Value
 of Unearned
 Shares, Units
 or Other
 Rights That
 Have Not
 Vested ($)

 (a)

 (b)

 (c)

 (d)

 (e)

 (f)

 (g)

 (h)

 (i)

 (j)

 Current Named Executive Officers

 Mick Ruxin

 469,738,712
 (2)

 -
 (1)

 -

 0.0036

 8/16/2032

 -

 -

 -

 -

 Faith Zaslavsky

 -

 -

 -

 -

 -

 -

 -

 -

 -

 Andrew Kucharchuk

 -

 -

 -

 -

 -

 -

 -

 -

 -

 Thomas Chilcott

 -

 -

 -

 -

 -

 -

 -

 -

 -

 (1)

 The
 options vest on the first anniversary of the grant date and become fully vested on May 1, 2023. The option awards remain exercisable
 until they expire ten years from the date of grant subject to earlier expiration following termination of Dr. Ruxin's contractual
 agreement.

 (2)

 All
 vested options are only exercisable upon the Company filing an S-8 to register the underlying shares.

 Long-Term
Incentive Plans, Retirement or Similar Benefit Plans

 There
are currently no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers,
except that we may reimburse our executive employees for up to 100% of their health insurance premiums under their individual policies.

 Our
directors, executive officers and employees may receive stock options at the discretion of our Board.

 Potential
Payments upon Termination or Change in Control

 Faith

 We
do not anticipate any payments to Ms. Zaslavsky being triggered upon a potential termination or change in control.

 We
do not anticipate any payments to Mr. Kucharchuk being triggered upon a potential termination or change in control.

 Compensation
of Directors

 During
the year ended September 30, 2023, we did not pay compensation to any of our non-employee directors in connection with their service
on our Board.

 ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 The
following table sets forth certain information regarding beneficial ownership of our common stock as of February 15, 2024, by (i) each
person known by us to be the beneficial owner of more than 5% of our outstanding common stock, (ii) each director and each of our Named
Executive Officers and (iii) all executive officers and directors as a group.

 The
number of shares of common stock beneficially owned by each person is determined under the rules of the SEC and the information is not
necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares as to
which such person has sole or shared voting power or investment power and also any shares which the individual has the right to acquire
within 60 days after the date hereof, through the exercise of any stock option, warrant or other right. Unless otherwise indicated, each
person has sole investment and voting power (or shares such power with his or her spouse) with respect to the shares set forth in the
following table. The inclusion herein of any shares deemed beneficially owned does not constitute an admission of beneficial ownership
of those shares.

 Name and Address of Beneficial Owner (1)

 Common Stock Beneficial Ownership (2)

 Percent of Class

 5% Stockholders

 Avant Diagnostics, Inc.(3)

 5,081,549,184

 70.1
 %

 Douglas Mergenthaler

 1,099,710,968
 (4)

 15.2
 %

 Named Executive Officers and Directors:

 Mick Ruxin(3)

 5,081,549,184

 70.1
 %

 Faith Zaslavsky

 -

 -

 Jeffrey Busch

 -
 (5)

 -

 Thomas Chilcott

 -

 -

 Yvonne Fors

 -

 -

 Andrew Kucharchuk

 290,000

 - - *

 Matthew Schwartz

 -

 -

 Danica Holly

 -

 -

 All executive officers and directors as a group (eight persons)

 -

 -

 *
Indicates less than 1%

 (1)

 Unless
 otherwise indicated, the business address of each person listed is in care of Theralink Technologies, Inc., 15000 W. 6 th
 Avenue, Suite 400, Golden, CO 80401.

 (2)

 The
 number and percentage of shares beneficially owned are determined in accordance with Rule 13d-3 of the Securities Exchange Act of
 1934, as amended (the "Exchange Act"), and the information is not necessarily indicative of beneficial ownership for
 any other purpose. Under such rule, beneficial ownership includes any shares over which the individual or entity has voting power
 or investment power and any shares of common stock that the individual has the right to acquire within 60 days of February 15, 2024,
 through the exercise of any stock option or other right. As of February 15, 2024, 6,151,499,919 shares of the Company's common
 stock were outstanding.

 (3)

 The
 address of Avant Diagnosticsm Inc. ("Avant") is P.O, Box 869, Morrison, CO 80465. Represents 5,081,549,184 shares of
 common stock held of record by Avant. Mick Ruxin is the chief executive officer and sole
 director of Avant and as such could be deemed to have voting and dispositive power with respect to the shares held by Avant. Dr.
 Ruxin disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

 (4)

 The
 address for Douglas Mergenthaler is Ashton Capital Corporation, 1201 Monster Road SW, Suite 350, Renton, WA 98057. All securities
 held by Mr. Mergenthaler are held either directly or indirectly through Aston Capital, an investment fund that Mr. Mergenthaler controls.
 The amount shown includes: (1) 656,674,588 shares of common stock issuable upon the exercise of warrants that expire on November
 27, 2024 with an exercise price of $.00214; (2) 63,897,764 shares of common stock issuable upon the exercise of warrants that expire
 on May 12, 2026, at an exercise price of $.003 and (3) 63,897,764 shares of common stock issuable upon the exercise of warrants that
 expire on May 12, 2026, at an exercise price of $.003. (4) 273,224,045 shares of common stock issuable upon the exercise of warrants
 that expire on November 1, 2026, at an exercise price of $.003. (5) 42,016,807 shares of common stock issuable upon the exercise
 of warrants that expire on April 1, 2027, at an exercise price of $.003. This number excludes $9,814,741 in convertible debentures
 and 2,277,755,254 warrants that are not currently convertible or exercisable.

 (5)

 This
 number excludes $175,872 in convertible debentures and 50,249,523 warrants that are not currently convertible or exercisable.

 ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 Related
Party Transactions

 On
October 21, 2021, the Company entered into a Promissory Note Agreement with Jeffrey Busch who serves as a member of the Board of Directors
and a related party, for a principal balance of $150,000. During the year ended September 30, 2022, the Company fully paid the outstanding
balance on the note. As of September 30, 2022, the note had no outstanding balance.

 On
November 1, 2021, the Company entered into a Securities Purchase Agreement with an affiliated investor, who is an existing shareholder
("Affiliated Investor"), to purchase a convertible note (the "Note") and accompanying warrant for 54,644,811
shares of commons stock (the "Warrant"), for an aggregate investment amount of $1,000,000. The Note has a principal value
of $1,000,000 and bears an interest rate of 8% per annum (which shall increase to 10% per year upon the occurrence of an "Event
of Default" (as defined in the Note)) and shall mature on November 1, 2026 (the "Maturity Date"). As of September 30,
2022, the First November 2021 Notes had an outstanding principal of $1,000,000 and accrued interest of $20,164 and are included in the
accompanying balance sheet at $140,093 as a long-term convertible note payable - related party, net of discount in the amount of $859,907
(see Note 8 to the consoldiated financial statements filed in the 2023 10-K) as of September 30, 2022. On November 29, 2022, the First
November 2021 Notes were exchanged for a new convertible debenture (see below).

 On
January 26, 2022, a notice and request for consent regarding a change in offering terms was sent by the Company to the First November
2021 Investor. Upon the approval of the First November 2021 Investor, the Company modified the terms of the First November 2021 SPA which
increased the warrants issuable from 20% to 100% of the common stock issuable upon conversion of the notes purchased. As a result, the
First November 2021 Investor received additional cashless-exercisable warrants equal to 80% of the common stock issuable upon conversion
of the First November 2021 Notes. The Company issued additional warrants to purchase up to 218,579,234 shares of common stock to the
First November 2021 Investor which increased the total relative fair value of all warrants in total by $34,630 recorded as debt discount
which is being amortized over the life of the First November 2021 Notes.

 On
April 5, 2022, pursuant to the First April 2022 SPA, Matthew Schwartz, a member of the Board of Directors and a related party, purchased
a convertible note with principal amount of $100,000 with accompanying First April 2022 Warrants to purchase 4,201,681 shares of common
stock. The Company received net proceeds of $100,000 on March 24, 2022. As of September 30, 2022, the First April 2022 Note had an outstanding
principal balance of $100,000 and accrued interest of $3,901 and is reflected in the accompanying balance sheet at $18,959 as a long-term
convertible note payable - related party, net of discount in the amount of $81,041 (see Note 8 to the consoldiated financial statements
filed in the 2023 10-K) as of September 30, 2022. On November 29, 2022, the First April 2022 Note was exchanged for a new convertible
debenture (see below).

 On
May 9, 2022, pursuant to the May 2022 SPA the May 2022 Investor purchased four convertible notes for an aggregate investment amount of
$1,000,000 with accompanying May 2022 Warrants to purchase shares of common stock equal to 20% of the number of the total shares of common
stock issuable upon the conversion of the May 2022 Notes. During the year ended September 30, 2022, the Company received an aggregate
of $1,000,000 of proceeds and issued an aggregate of 42,016,808 of the May 2022 Warrants. As of September 30, 2022, the May 2022 Notes
had an aggregate outstanding principal balance of $1,000,000 and accrued interest of $20,110 and are included in the accompanying balance
sheet at $834,803 as a long-term convertible note payable - related party, net of discount in the amount of $165,197 (see Note 8 to the
consoldiated financial statements filed in the 2023 10-K) as of September 30, 2022. On November 29, 2022, the May 2022 Note was exchanged
for a new convertible debenture (see below).

 On
June 15, 2022, pursuant to the June 2022 SPA, Danica Holley, a member of the Board of Directors and a related party, purchased a convertible
note with principal of $50,000 with accompanying June 2022 Warrants to purchase 2,100,840 shares of common stock. As of September 30,
2022, the June 2022 Note had an outstanding principal balance of $50,000 and accrued interest of $1,173. The June 2022 Note is included
in the accompanying balance sheet at $44,438 as a long-term convertible note payable - related party, net of discount in the amount of
$5,562 (see Note 8 to the consoldiated financial statements filed in the 2023 10-K) as of September 30, 2022. On November 29, 2022, the
June 2022 Note was exchanged for a new convertible debenture (see below).

 On
July 29, 2022, the Company entered into a Demand Promissory Note Agreement with Jeffrey Busch who serves as a member of the Board of
Directors and a related party, for a principal balance of $125,000, and on September 2, 2022, the Company entered into a second Demand
Promissory Note Agreement with Jeffrey Busch for a principal balance of $150,000 (collectively referred to as the "Busch Notes").
The Busch Notes bore an annual interest rate of 8% and were payable on demand. The outstanding principal and accrued interest on the
Busch Notes were contingently convertible, in full, at the option of the lender, into the same security issued by the Company in its
next private placement of equity or equity backed securities at any time after the inception date. As of September 30, 2022, the Busch
Notes had an outstanding principal balance of $275,000 and accrued interest of $2,683 and are included in the accompanying balance sheet
as a short-term convertible note payable - related party. On November 29, 2022, the Busch Notes were exchanged for a new convertible
debenture (see below).

 On
August 11, 2022, the Company entered into a Demand Note with an affiliated investor, who is an existing shareholder ("Affiliated
Investor"), to purchase a convertible note (the "Note"), for an aggregate investment amount of $375,000. The Note has
a principal value of $375,000 and bears an interest rate of 8% per annum and is payable on the demand of the holder. As of September
30, 2022, this note had an outstanding principal balance of $375,000 and accrued interest of $4,110 and is included in the accompanying
balance sheet as a short-term convertible note payable - related party. On November 29, 2022, this note was exchanged for a new convertible
debenture (see below).

 On
September 2, 2022, the Company entered into a Demand Note with an affiliated investor, who is an existing shareholder ("Affiliated
Investor"), to purchase a convertible note (the "Note"), for an aggregate investment amount of $350,000. The Note has
a principal value of $350,000 and bears an interest rate of 8% per annum and is payable on the demand of the holder. As of September
30, 2022, this note had an outstanding principal balance of $350,000 and accrued interest of $2,148 and is included in the accompanying
balance sheet as a short-term convertible note payable - related party. On November 29, 2022, this note was exchanged for a new convertible
debenture (see below).

 On
November 1, 2022, the Company entered into a Demand Promissory Note Agreements with two related parties, who are affiliate stockholders,
for a principal balance of $120,000. The notes bore an annual interest rate of 8% and were payable on demand. The outstanding principal
and accrued interest of the notes was contingently convertible, in full, at the option of the lender, into the same security issued by
the Company in its next private placement of equity or equity backed securities at any time after the inception date. In December 2022,
these short-term loans were repaid.

 On
November 29, 2022, in connection with the Securities Exchange Agreements and New Convertible Debt discussed below, the May 2021 Warrants,
First November 2021 Warrants, First April 2022 Warrants, May 2022 Warrants, and June 2022 Warrants, aggregating 385,441,138 warrants,
were amended to reduce the exercise price to $0.003 per share. Additionally, 63,897,764 warrants issued in connection with Series F preferred
stock were amended to reduce the exercise price to $0.003 per share. In conjunction with the price reduction, the price protection feature
for all these warrants was eliminated. All other terms of the warrants remained the same. As a result of the November 29, 2022, amendment
to the exercise price, the Company calculated the difference between the warrants' fair values on November 29, 2022, the date of
the amendment, using the then current exercise price ranging from $0.00366 to $0.00476 and the new exercise price of $0.003 and determined
that the difference was insignificant.

Exchange Agreements and New Related Party Convertible Debentures and Warrants dated November 29, 2022

 On
November 29, 2022, the Company consummated the initial closing of a private placement offering pursuant to the terms and conditions of
that certain Securities Purchase Agreement, dated as of November 29, 2022, by and among the Company, certain related party accredited
investors (the "Related Party Purchasers") and Cavalry Fund I Management LLC, a Delaware limited liability company, in its
capacity as collateral agent.. At the initial closing, the Company sold the related party Purchasers (i) 10% Original Issue Discount
Senior Secured Convertible Debentures (the "New Related Party Debentures") in an aggregate principal amount of $550,000 and
(ii) warrants (the "New Related Party Warrants") to purchase up to 157,142,857 shares of common stock of the Company, subject
to adjustments provided by the Warrants, which represents 100% warrant coverage. The Company received a total of $412,092 in net proceeds
at the Initial Offering from the Related Party Purchasers, net of the Original Issue Discount of $50,000, commissions of $58,200 and
other offering costs of $29,708.

 On
November 29, 2022, the Company entered into Securities Exchange Agreements with the above related party investors, whereby the May 2021
Note, the First November 2021 Notes, the First April 2022 Note, the May 2022 Notes, the June 2022 Note, the Busch Notes, the August 11,
2022 Demand Promissory Note, and the September 2, 2022 Demand Promissory Note with an aggregate principal amount of $4,150,000 (the "Exchanged
Related Party Notes") and accrued interest payable of $120,750 were exchanged for New Related Party Debentures. Additionally, on
November 29, 2022, in order to induce the related party investors to exchange the respective convertible notes into the Related Party
Debentures, the aggregate principal amount of the Exchanged Related Party Notes and accrued interest payable was increased by 15% (and
the August 11, 2022 and September 2, 2022 Demand Promissory Notes were issued with 10% OID), or $589,505, for New Related Party Debentures
with an aggregate principal amount of $4,860,255.

 On
November 29, 2022, the Company entered into Securities Exchange Agreements with related party preferred stockholders, whereby related
party holders of 1,000 shares of Series E preferred stock with a stated value of $2,000,000 and accrued dividends payable of $66,630,
and related party holders of 500 shares of Series F preferred stock with a stated value of $1,000,000 and accrued dividends payable of
$33,315 were exchanged for the New Related Party Debentures. Additionally, on November 29, 2022, in order to induce the related party
preferred stockholders to exchange their respective preferred shares into the New Related Party Debentures, the aggregate stated value
and accrued dividends payable were increased by 15%, or $464,992, for new Related Party Debentures with an aggregate principal amount
of $3,564,937.

 On
April 11, 2023, the Company consummated a third closing of the Offering pursuant to the terms and conditions of that certain Purchase
Agreement, dated as of November 29, 2022, by and among the Company and Jeffrey Busch (the "Third Closing Related Party Purchaser").
At the third closing, the Company sold the Purchaser (i) a New Debenture with a principal amount of $155,100 (the "April 2023 Related
Party Debenture") and (ii) Warrants to purchase up to 44,314,286 shares of Common Stock, subject to adjustments provided by the
Warrants, which represents 100% warrant coverage. The Company received a total of $141,000 in net proceeds at the Third Offering, net
of a 10% original issue discount of $14,100.

 The
November 29, 2022, New Related Party Debentures and April 2023 Related Party Debenture matured on November 29, 2023, subject to a three-month
extension at the sole discretion of the Company. On November 27, 2023, the Company announced its intention to automatically extend the
Maturity Date of the Debentures for an additional three-month period such that the Debentures shall be due and payable on February 29,
2024 (See Note 14 to the consoldiated financial statements filed in the 2023 10-K).

 The
Company's obligations under the New Related Party Debentures and April 2023 Related Party Debenture are secured by a first priority
lien on all the assets of the Company pursuant to that certain Security Agreement, dated November 29, 2022 (the "Security Agreement")
by and among the Company, the Debenture holders and the Collateral Agent. In connection with the issuance of the IMAC Note, the Company,
Collateral Agent and the holders of a majority of the outstanding New Related Party Debentures agreed to amend and restate the Original
Security Agreement to include the IMAC Note, pursuant to the Amended and Restated Security Agreement dated as of August 16, 2023 by and
between the Company, IMAC and the Collateral Agent.

 In
connection with the Securities Exchange Agreements with related parties for the exchange of the convertible notes and preferred shares
for the New Related Party Debentures and for the April 2023 Related party Debenture discussed above, the Company issued an aggregate
of 2,608,654,988 warrants. The New Related Party Warrants and April 2023 Related Party Warrant are exercisable for five years and six
months from the earlier of the maturity date of the New Related Party Debentures and the closing of the Qualified Financing, at an exercise
price equal to (i) in the event that a Qualified Offering is consummated prior to the exercise of the New Related Party Warrant and April
2023 Related Party Warrant, the price per share at which the Qualified Offering is made ("Qualified Offering Price"), or
(ii) in the event that no Qualified Offering has been consummated, the lower of: (A) $0.003 per share and (B) an amount equal to 70%
of the average of the VWAP (or 50% of the average of the VWAP if an event of default has occurred and has not been cured) for the Common
Stock over the ten Trading Days preceding the date of the delivery of the applicable exercise notice. If there is no effective registration
statement covering the resale of the shares underlying the New Related Party Warrants and April 2023 Related Party Warrant within 180
days following the closing of the Qualified Offering: (i) exercise may be via cashless exercise, and (ii) 5% additional Warrants will
be issued by the Company to the holders for any portion of each month without such effective registration statement, up to a maximum
of 25%. The New Related Party Warrants and April 2023 Related Party Warrant contain certain price protection provisions providing for
adjustment in the amount of securities issuable upon exercise of the New Related Party Warrants and April 2023 Related Party Warrant
in case of certain future dilutive events or stock-splits and dividends.

 As
discussed above, on November 29, 2022, in order to induce the related party investors to exchange their respective convertible notes
and preferred stock into the New Related Party Debentures, the aggregate principal amount and accrued interest payable of the exchanged
convertible notes, and the stated value and accrued dividends of exchanged preferred stock was increased by 15% (the August 11, 2022
and September 2, 2022 Demand Promissory Notes were issued with 10% OID), or an aggregate amount of $1,046,167. This inducement fee was
included in loss from debt extinguishment on the accompanying statement of operations during the year ended September 30, 2023. Additionally,
the remaining debt discount on exchanged related party notes of $1,768,379 was written off and included in loss from debt extinguishment
on the accompanying statement of operations for the year-ended September 30, 2023.

 IMAC
Convertible Secured Note

 On
August 16, 2023, the Company entered into a Convertible Secured Promissory Note with IMAC Holdings, Inc. for a total principal amount
of $2,560,500. The note bears interest at 6% per annum and matures on August 16, 2024. Accrued interest is payable at the option of the
holder on a quarterly basis. Upon maturity, in lieu of payment or as partial payment, the Company may, upon notice to the Holder, elect
to convert some or all of the outstanding principal amount plus accrued and unpaid interest under this Note into a number of shares of
the Company's common stock at a price per share of $0.00313.

 Upon
the closing of the stock-for-stock reverse merger transaction contemplated in that certain Agreement and Plan of Merger, dated May 23,
2023, by and between the Company and the Holder, pursuant to which the Company will merge with a newly-formed wholly-owned subsidiary
of the Holder and in which the Company will survive as a wholly-owned subsidiary of the Holder, the Conversion Amount shall automatically
be converted into fully-paid and non-assessable shares of Common Stock at a price per share of $.00313.

 This
Note is secured by all of the assets of the Company pursuant to that certain Amended and Restated Security Agreement (as amended, restated
or otherwise modified from time to time, the " Security Agreement ") dated as of the Issue Date, between the
Company and the Holder and each of the other parties thereto from time to time as specified in such Security Agreement. This Note shall
rank pari passu as to the payment of principal and interest to those certain 10.0% Original Issue Discount Senior Secured Convertible
Debentures of the Company issued pursuant to that certain Securities Purchase Agreement, dated as of November 29, 2022, as amended, and
that certain Securities Exchange Agreement, dated as of November 29, 2022. This Note shall rank senior to any unsecured debt of the Company.

 On
August 28, 2023, the Company repaid $250,000 of the note.

 As
of September 30, 2023, the note has an outstanding principal balance of $2,310,500, which is included in convertible notes - related
parties in the accompanying balance sheets, and has accrued interest payable of $17,708.

 Policies
and Procedures for Related Party Transactions

 We
have adopted a policy that our executive officers, directors, nominees for election as directors, beneficial owners of more than 5% of
any class of our common stock and any member of the immediate family of any of the foregoing persons, are not permitted to enter into
a related party transaction with us without the prior consent of our Board. If advance approval is not feasible then the related party
transaction will be considered at the next regularly scheduled Board meeting. In approving or rejecting any such proposal, our Board
is to consider the relevant facts and circumstances available and deemed relevant, including, but not limited to, whether the transaction
is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and
the extent of the related party's interest in the transaction.

Independence

 Because
the Company's common stock is not currently listed on a national securities exchange, the Company has used the definition of "independence"
of The NASDAQ Stock Market to make this determination. NASDAQ Listing Rule 5605(a)(2) provides that an "independent director"
is a person other than an officer or employee of the company or any other individual having a relationship which, in the opinion of the
Company's Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.
The NASDAQ listing rules provide that a director cannot be considered independent if:

 the
 director is, or at any time during the past three years was, an employee of the Company;

 the
 director or a family member of the director accepted any compensation from the Company in excess of $120,000 during any period of
 12 consecutive months within the three years preceding the independence determination (subject to certain exclusions, including,
 among other things, compensation for board or board committee service);

 a
 family member of the director is, or at any time during the past three years was, an executive officer of the Company;

 the
 director or a family member of the director is a partner in, controlling stockholder of, or an executive officer of an entity to
 which the Company made, or from which the Company received, payments in the current or any of the past three fiscal years that exceed
 5% of the recipient's consolidated gross revenue for that year or $200,000, whichever is greater (subject to certain exclusions);

 the
 director or a family member of the director is employed as an executive officer of an entity where, at any time during the past three
 years, any of the executive officers of the Company served on the compensation committee of such other entity; or

 the
 director or a family member of the director is a current partner of the Company's outside auditor, or at any time during the
 past three years was a partner or employee of the Company's outside auditor, and who worked on the Company's audit.

 Based
on this review, the Company has three independent directors pursuant to the requirements of the NASDAQ Stock Market, Matthew Schwartz,
Danica Holley and Yvonne Fors.

 ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 The
following table sets forth the fees billed to our Company for the years ended September 30, 2023 and 2022 for professional services rendered
by Salberg & Company, P.A., our independent registered public accounting firms:

 Fees

 2023

 2022

 Audit Fees

 $
 89,800

 $
 81,500

 Audit Related Fees

 12,800

 1,000

 Tax Fees

 —

 —

 Other Fees

 —

 —

 Total Fees

 $
 102,600

 $
 82,500

 Audit
Fees

 Audit
fees were for professional services rendered for the audits of our annual financial statements and for review of our quarterly financial
statements during the 2023 and 2022 fiscal years.

 Audit-related
Fees

 This
category consists of assurance and related services by the independent registered public accounting firm that are reasonably related
to the performance of the audit or review of our financial statements and are not reported above under "Audit Fees".

 Tax
Fees

 As
our independent registered public accountants did not provide any services to us for tax compliance, tax advice and tax planning during
the fiscal years ended September 30, 2023, and 2022, no tax fees were billed or paid during those fiscal years.

 All
Other Fees

 Our
independent registered public accountants did not provide any products and services not disclosed in the table above during the 2023
and 2022 fiscal years. As a result, there were no other fees billed or paid during those fiscal years.

 Policy
on Pre-Approval of Services of Independent Registered Public Accounting Firm

 Prior
to the engagement, the Board pre-approves these services by category of service. The fees are budgeted, and the Board requires the independent
registered public accounting firm and management to report actual fees versus the budget periodically throughout the year by category
of service. During the year, circumstances may arise when it may become necessary to engage the independent registered public accounting
firm for additional services not contemplated in the original pre-approval. In those instances, the Board requires specific pre-approval
before engaging the independent registered public accounting firm.

 The
Board may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must report,
for informational purposes only, any pre-approval decisions to the Board at its next scheduled meeting.

 Our
Board has considered the nature and amount of fees billed by our independent registered public accounting firm and believe that the provision
of services for activities unrelated to the audit is compatible with maintaining their respective independence.

 PART
IV

 ITEM
15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES

 (a)

 1.

 Financial
 Statements

 Our
consolidated financial statements are set forth in Part II, Item 8 of our Annual Report on Form 10-K and are incorporated herein by reference.

 2.

 Financial
 Statement Schedules

 No financial statement schedules have been filed as part of our Annual Report on Form 10-K because they are not applicable or are not
required or because the information is otherwise included herein.

 3.

 Exhibits
required by Regulation S-K (including those incorporated by reference).

 Exhibit

 Incorporated
 by Reference

 Filed
 or Furnished

 Number

 Exhibit
 Description

 Form

 Exhibit

 Filing
 Date

 Herewith

 2.1

 Agreement and Plan of Merger, dated as of May 23, 2023, by and among IMAC Holdings, Inc., IMAC Merger Sub, LLC and Theralink Technologies, Inc.

 2.1

 05/26/2023

 3.1

 Amended and Restated Articles of Incorporation, as amended

 3.1

 01/13/2022

 3.2

 Amended and Restated Bylaws

 3.1

 11/01/2013

 4.1

 Description of Common Stock

 4.1

 4.2

 Form of Warrant

 4.1

 06/11/2020

 4.3

 Exchange Warrant, dated June 5, 2020

 4.2

 06/11/2020

 4.4

 Common Stock Purchase Warrant, issued May 12, 2021

 4.2

 05/19/2021

 4.5

 Common Stock Purchase Warrant, dated July 30, 2021

 4.1

 08/06/2021

 4.6

 Form of Common Stock Purchase Warrant

 4.2

 11/05/2021

 4.7

 Form of Common Stock Purchase Warrant for April 2022

 4.2

 05/23/2022

 4.8

 Form of 10% Original Issue Discount Senior Secured Convertible Debentures

 4.1

 4.9

 Form of Common Stock Purchase Warrant

 4.2

 4.10

 Form of 10% Original Issue Discount Senior Secured Convertible Debentures (Exchanged Debentures)

 4.3

 4.11

 Secured Convertible Promissory Note dated August 16, 2023

 4.1

 08/21/2023

 10.1

 Employment Agreement, dated June 5, 2020 by and between Jeffrey Busch and OncBioMune Pharmaceuticals, Inc.*

 10.14

 09/27/2021

 10.2

 Placement Agency Agreement by and between the Company and Joseph Gunnar & Co.

 10.1

 10.3

 Form of Securities Purchase Agreement

 10.2

 10.4

 Offer Letter between the Company and Faith Zaslavsky, dated December 5, 2022

 10.1

 12/09/2022

 10.5

 Amended and Restated Security Agreement

 10.1

 08/21/2023

 21.1

 List of Subsidiaries

 21.1

 31.1

 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002.

 X

 31.2

 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002.

 X

 32.1

 Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act Of 2002.

 X

 101.INS

 101.SCH

 101.CAL

 101.DEF

 101.LAB

 101.PRE

 *
Management contract or compensatory plan or arrangement

 SIGNATURES

 Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.

 THERALINK
 TECHNOLOGIES, INC.

 Dated:
 February 15, 2024

 By:

 /s/
 Faith Zaslavsky

 Faith

 Chief
 Executive Officer

 Dated:
February 15, 2024

 By:

 /s/
 Andrew Kucharchuk

 Chief
 Financial Officer